Zymeworks (NYSE:ZYME – Get Free Report) had its price objective decreased by analysts at Wells Fargo & Company from $14.00 to $12.00 in a report released on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 30.43% from the stock’s current price.
Zymeworks Price Performance
Shares of ZYME opened at $9.20 on Friday. Zymeworks has a one year low of $6.01 and a one year high of $13.14. The firm has a market capitalization of $649.23 million, a P/E ratio of -5.14 and a beta of 1.16. The business has a fifty day moving average of $10.12 and a 200 day moving average of $9.71.
Zymeworks (NYSE:ZYME – Get Free Report) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.19. Zymeworks had a negative return on equity of 28.24% and a negative net margin of 249.63%. The company had revenue of $16.93 million during the quarter, compared to analyst estimates of $18.32 million. Analysts expect that Zymeworks will post -1.04 EPS for the current fiscal year.
Institutional Trading of Zymeworks
Zymeworks Company Profile
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
See Also
- Five stocks we like better than Zymeworks
- 3 Warren Buffett Stocks to Buy Now
- MarketBeat Week in Review – 4/29 – 5/3
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- How Technical Indicators Can Help You Find Oversold Stocks
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.